Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients

Clinical Pharmacokinetics

Volumn 56, Issue 6, 2017, Pages 617-633

  Minichmayr, Iris K ^a,b   Schaeftlein, André ^a,b   Kuti, Joseph L ^c   Zeitlinger, Markus ^d   Kloft, Charlotte ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Graduate Research Training program PharMetrX   (Germany)

^c HARTFORD HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; LINEZOLID; ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DIABETIC FOOT; DIABETIC PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INTENSIFICATION; DRUG PENETRATION; DRUG TARGETING; FEMALE; HUMAN; INTERSTITIAL FLUID; INTERSTITIAL SPACE FLUID; MAJOR CLINICAL STUDY; MALE; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MUSCLE TISSUE; PHARMACODYNAMIC PARAMETERS; POPULATION; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS FAT; TISSUE DISTRIBUTION; ADIPOSE TISSUE; BACTERIAL INFECTION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; EXTRACELLULAR FLUID; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; NORMAL HUMAN; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; CYSTIC FIBROSIS; DIABETIC FOOT; EXTRACELLULAR FLUID; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LINEZOLID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; SEPSIS; YOUNG ADULT;

EID: 84991716276     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0463-7     Document Type: Article

References (62)

1. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42:1129–40.
2. ®: summary of product characteristics. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021132s027lbl.pdf. Accessed 28 Jul 2016.
3. Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos. 2007;35:1816–23.
4. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother. 2011;55:4170–5.
5. Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33:1529–33.
6. Stolle LB, Plock N, Joukhadar C, et al. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis. Scand J Infect Dis. 2008;40:24–9.
7. Chaurasia CS, Müller M, Bashaw ED, et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res. 2007;24:1014–25.
8. Tunblad K, Hammarlund-Udenaes M, Jonsson EN. An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res. 2004;21:1698–707.
9. Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605–10.
10. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411–23.
11. Di Paolo A, Malacarne P, Guidotti E, et al. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet. 2010;49:439–47.
12. Sandberg A, Jensen KS, Baudoux P, et al. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. J Antimicrob Chemother. 2010;65:962–73.
13. Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55:1867–73.
14. Boak LM, Rayner CR, Grayson ML, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother. 2014;58:2334–43.
15. Sisson L, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57:793–7.
16. Tsuji Y, Yukawa E, Hiraki Y, et al. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J Clin Pharmacol. 2013;53:967–73.
17. Keel RA, Schaeftlein A, Kloft C, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011;55:3393–8.
18. Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol. 2010;66:291–8.
19. Bhalodi AA, Papasavas PK, Tishler DS, et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013;57:1144–9.
20. Beringer P, Nguyen M, Hoem N, et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676–81.
21. Duffull SB, Wright DFB. What do we learn from repeated population analyses? Br J Clin Pharmacol. 2015;79:40–7.
22. Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003;56:639–52.
23. Eslam RB, Burian A, Vila G, et al. Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection. J Clin Pharmacol. 2014;54:1058–62.
24. Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother. 2008;61:173–6.
25. Dehghanyar P, Bu C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49:2367–71.
26. Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 2006;50:2455–63.
27. Plock N, Kloft C. Microdialysis: theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005;25:1–24.
28. Chaurasia CS. In vivo microdialysis sampling: theory and applications. Biomed Chromatogr. 1999;13:317–32.
29. Buerger C, Joukhadar C, Muller M, Kloft C. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B. 2003;796:155–64.
30. Schaeftlein A, Minichmayr IK, Kloft C. Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data. Eur J Pharm Sci. 2014;57:68–73.
31. Minichmayr IK, Schaeftlein A, Zeitlinger M, Kloft C. Population pharmacokinetics of linezolid in diabetic patients with soft tissue infections: are standard doses adequate? 23rd European Congress of Clinical Microbiology and Infectious Diseases. Poster P-927. 2013. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=10424. Accessed 6 Aug 2016.
32. Boselli E, Breilh D, Caillault-Sergent A, et al. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2012;67:1207–10.
33. Islinger F, Dehghanyar P, Sauermann R, et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents. 2006;27:108–12.
34. European Committee on Antimicrobial Susceptibility Testing. Linezolid: rationale for the clinical breakpoints, version 1.0. 2005. Available from: http://www.eucast.org/documents/rd. Accessed 8 Oct 2015.
35. Stenken JA, Lunte CE, Southard MZ, Ståhle L. Factors that influence microdialysis recovery: comparison of experimental and theoretical microdialysis recoveries in rat liver. J Pharm Sci. 1997;86:958–66.
36. Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008;31:122–9.
37. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004;48:281–4.
38. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci. 1998;20:149–60.
39. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51:481–99.
40. Traunmüller F, Schintler MV, Spendel S, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents. 2010;36:84–6.
41. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007;60:819–23.
42. Majcher-Peszynska J, Haase G, Sass M, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol. 2008;64:1093–100.
43. Yagi T, Naito T, Doi M, et al. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Agents. 2013;42:329–34.
44. Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44:242–7.
45. Luque S, Grau S, Alvarez-Lerma F, et al. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents. 2014;44:409–15.
46. Meagher AK, Forrest A, Rayner CR, et al. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47:548–53.
47. Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071–8.
48. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55:333–40.
49. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58:119–33.
50. Huisinga W, Solms A, Fronton L, Pilari S. Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics Syst Pharmacol. 2012;1:e4.
51. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29:385–91.
52. Zeitlinger MA, Dehghanyar P, Mayer BX, et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother. 2003;47:3548–53.
53. Müller M, Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441–53.
54. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother. 2006;50:1372–5.
55. Stein GE, Throckmorton JK, Scharmen AE, et al. Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother. 2013;68:2852–8.
56. Morata L, Cuesta M, Rojas JF, et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother. 2013;57:1913–7.
57. Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36:179–81.
58. Dong H, Wang X, Dong Y, et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents. 2011;38:296–300.
59. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–53.
60. Kees MG, Minichmayr IK, Moritz S, et al. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J Clin Pharmacol. 2016;56:307–15.
61. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
62. FDA. Guidance for industry: pharmacokinetics in patients with impaired renal function. 1998. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf. Accessed 1 Aug 2016.